These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 31262926

  • 1. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.
    Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, DI Raimondo F, Manzella L.
    Anticancer Res; 2019 Jul; 39(7):3949-3954. PubMed ID: 31262926
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A, Minervini CF, Delia M, Cumbo C, Orsini P, Specchia G, Albano F.
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [Abstract] [Full Text] [Related]

  • 5. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
    Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N.
    Oncology; 2018 Sep; 94(2):85-91. PubMed ID: 29151104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [Abstract] [Full Text] [Related]

  • 8. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X, Pan J, Qiu H, Cen J, Xue Y, Chen S, Shen H, Yao L, Zhang J, Wu Y, Chen Y.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [Abstract] [Full Text] [Related]

  • 9. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R, Galal A.
    BMC Cancer; 2018 Nov 12; 18(1):1097. PubMed ID: 30419862
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.
    BMC Cancer; 2016 Aug 02; 16():572. PubMed ID: 27485109
    [Abstract] [Full Text] [Related]

  • 12. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ.
    Br J Haematol; 2018 Sep 02; 182(5):693-700. PubMed ID: 29974949
    [Abstract] [Full Text] [Related]

  • 13. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 02; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 14. Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.
    Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, Di Raimondo F, Manzella L.
    Oncol Lett; 2019 Sep 02; 18(3):2648-2653. PubMed ID: 31404304
    [Abstract] [Full Text] [Related]

  • 15. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 02; 16 Suppl():S96-S100. PubMed ID: 27131622
    [Abstract] [Full Text] [Related]

  • 16. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL, Langabeer SE, Bolger K, Haslam K, Crampe M, Kelly J, Morrell R.
    Med Oncol; 2015 Feb 02; 32(2):452. PubMed ID: 25579165
    [Abstract] [Full Text] [Related]

  • 17. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G, GIMEMA CML Working Party.
    Am J Hematol; 2017 Aug 02; 92(8):797-805. PubMed ID: 28466557
    [Abstract] [Full Text] [Related]

  • 18. Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib.
    Ikeda K, Harada-Shirado K, Matsumoto H, Noji H, Ogawa K, Takeishi Y.
    J Clin Oncol; 2016 May 10; 34(14):e130-3. PubMed ID: 24752059
    [No Abstract] [Full Text] [Related]

  • 19. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Xue M, Wang Q, Huo L, Wen L, Yang X, Wu Q, Pan J, Cen J, Ruan C, Wu D, Chen S.
    Leuk Lymphoma; 2019 Dec 10; 60(12):3051-3057. PubMed ID: 31258010
    [Abstract] [Full Text] [Related]

  • 20. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
    Bayrak AG, Daglar Aday A, Yavuz AS, Nalcaci M, Ozbalak MM, Cefle K, Ozturk S, Palanduz S.
    Leuk Res; 2021 Dec 10; 111():106725. PubMed ID: 34634595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.